Cargando…

Mutant p53 in colon cancer

The accumulation of genetic alterations in driver genes is responsible for the development and malignant progression of colorectal cancer. Comprehensive genome analyses have revealed the driver genes, including APC, KRAS, TGFBR2, and TP53, whose mutations are frequently found in human colorectal can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakayama, Mizuho, Oshima, Masanobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Invited Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487790/ https://www.ncbi.nlm.nih.gov/pubmed/30496442 http://dx.doi.org/10.1093/jmcb/mjy075

Ejemplares similares

Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties
por: Nakayama, Mizuho, et al.
Publicado: (2020)

Mutant p53 in cancer therapy—the barrier or the path
por: Zhou, Xiang, et al.
Publicado: (2018)

Frequent loss of metastatic ability in subclones of Apc, Kras, Tgfbr2, and Trp53 mutant intestinal tumor organoids
por: Morita, Atsuya, et al.
Publicado: (2023)

Understanding p53 functions through p53 antibodies
por: Sabapathy, Kanaga, et al.
Publicado: (2019)

Drugging in the absence of p53
por: Aning, Obed Akwasi, et al.
Publicado: (2019)

Tumor suppressor p53 and metabolism
por: Liu, Juan, et al.
Publicado: (2018)

The role of p53 in developmental syndromes
por: Bowen, Margot E, et al.
Publicado: (2019)

Genetic Alterations and Microenvironment that Drive Malignant Progression of Colorectal Cancer: Lessons from Mouse and Organoid Models
por: Nakayama, Mizuho, et al.
Publicado: (2022)

Genetic and nongenetic mechanisms for colorectal cancer evolution
por: Kok, Sau Yee, et al.
Publicado: (2023)

The MDM2-p53 pathway revisited
por: Nag, Subhasree, et al.
Publicado: (2013)

Small molecule activators of the p53 response
por: Ladds, Marcus J G W, et al.
Publicado: (2019)

p53 as a hub in cellular redox regulation and therapeutic target in cancer
por: Eriksson, Sofi E, et al.
Publicado: (2019)

Functional relationship between p53 and RUNX proteins
por: Bae, Suk-Chul, et al.
Publicado: (2018)

Mouse modelling of the MDM2/MDMX−p53 signalling axis
por: Tackmann, Nicole R., et al.
Publicado: (2017)

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?
por: Haronikova, Lucia, et al.
Publicado: (2021)

Discussion of some ‘knowns’ and some ‘unknowns’ about the tumour suppressor p53
por: Lieschke, Elizabeth, et al.
Publicado: (2018)

Regulation of kidney development by the Mdm2/Mdm4–p53 axis
por: El-Dahr, Samir, et al.
Publicado: (2017)

It takes a team: a gain-of-function story of p53-R249S
por: Wang, Huai, et al.
Publicado: (2019)

Roles of computational modelling in understanding p53 structure, biology, and its therapeutic targeting
por: Tan, Yaw Sing, et al.
Publicado: (2019)

Laparoscopic surgery for colon cancer
por: Millo, Paolo, et al.
Publicado: (2013)

Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation
por: Nakayama, M, et al.
Publicado: (2017)

Mutant p53 as an Antigen in Cancer Immunotherapy
por: Sobhani, Navid, et al.
Publicado: (2020)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

Treating p53 Mutant Aggregation-Associated Cancer
por: Kanapathipillai, Mathumai
Publicado: (2018)

The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment
por: Li, Dan-Dan, et al.
Publicado: (2012)

Mutant p53 partners in crime
por: Kim, Michael P, et al.
Publicado: (2018)

p53 tetramerization: at the center of the dominant-negative effect of mutant p53
por: Gencel-Augusto, Jovanka, et al.
Publicado: (2020)

Mutant p53 as a guardian of the cancer cell
por: Mantovani, Fiamma, et al.
Publicado: (2018)

TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell
por: Lei, Guoqiong, et al.
Publicado: (2021)

A Novel P53-Related Activity in a Colon Adenocarcinoma Cell Line With Mutant P53
por: Gartel, Andrei L., et al.
Publicado: (2001)

Complexes formed by mutant p53 and their roles in breast cancer
por: Bellazzo, Arianna, et al.
Publicado: (2018)

Gain-of-function mutant p53 in cancer progression and therapy
por: Zhang, Cen, et al.
Publicado: (2020)

The Function of the Mutant p53-R175H in Cancer
por: Chiang, Yen-Ting, et al.
Publicado: (2021)

GOF Mutant p53 in Cancers: A Therapeutic Challenge
por: Dolma, Lobsang, et al.
Publicado: (2022)

Characterization of RNF43 frameshift mutations that drive Wnt ligand‐ and R‐spondin‐dependent colon cancer
por: Yamamoto, Daisuke, et al.
Publicado: (2022)

Functional loss of p53 cooperates with the in vivo microenvironment to promote malignant progression of gastric cancers
por: Ohtsuka, Junko, et al.
Publicado: (2018)

Mutant p53 in cell-cell interactions
por: Pilley, Steven, et al.
Publicado: (2021)

Dysregulated Phosphorylation of p53, Autophagy and Stemness Attributes the Mutant p53 Harboring Colon Cancer Cells Impaired Sensitivity to Oxaliplatin
por: Therachiyil, Lubna, et al.
Publicado: (2020)

The rebel angel: mutant p53 as the driving oncogene in breast cancer
por: Walerych, Dawid, et al.
Publicado: (2012)

The aggregation of mutant p53 produces prion-like properties in cancer
por: Rangel, Luciana P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_q74aggp2pj57ruk5lt0u3v0vp1